Cardiovascular and metabolic safety profiles of the fluoroquinolones

Alessandra Pugi, Loreta Longo, Alessandro Bartoloni, Gian Maria Rossolini, Alessandro Mugelli, Alfredo Vannacci, Francesco Lapi

Research output: Contribution to journalArticlepeer-review


Introduction: Certain fluoroquinolones share similar indications of use. A comparison among Cardiovascular and metabolic (i.e., dysglycemia) safety profiles of the fluoroquinolones might be particularly useful for the prescribers' decision-making process as well as to hypothesize future researcher purposes. Areas covered: A literature search was conducted using keywords apt to identify information on safety profile of the fluoroquinolones. Publications concerned with descriptive and etiological surveys were manually reviewed. Expert opinion: Cardiac alterations and blood glucose impairments might be associated with any fluoroquinolone. However, the benefit/risk profile of these agents could be stratified for the single compounds. Several predisposing factors, such as diabetes, heart illnesses and their related pharmacotherapies, might exacerbate the risk of potentially serious adverse events. In this context, the opportunity of the more appropriate choice among different fluoroquinolones could be applicable.

Original languageEnglish
Pages (from-to)53-69
Number of pages17
JournalExpert Opinion on Drug Safety
Issue number1
Publication statusPublished - Jan 2012


  • Adverse event
  • Dysglycemia
  • Fluoroquinolones
  • Heart
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Cardiovascular and metabolic safety profiles of the fluoroquinolones'. Together they form a unique fingerprint.

Cite this